Aurobindo Pharma USA Inc. is recalling 792 bottles of Pioglitazone (Pioglitazone Tablets USP), a medication used to treat type 2 diabetes. The recall was initiated because the tablets were found to be superpotent, meaning they contain more active medicine than intended, and failed to meet quality specifications. No incidents or injuries have been reported in connection with this recall to date. Affected products were distributed nationwide in 500-count bottles.
Taking medication that is superpotent can lead to a higher dose than prescribed, which increases the risk of serious side effects like hypoglycemia (dangerously low blood sugar), potentially leading to dizziness, confusion, or loss of consciousness.
You have 2 options:
Recall #: D-0450-2022; Distributed by Aurobindo Pharma USA, Inc., East Windsor, NJ
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.